The Onshoring Advantage: 7 Forces Reshaping Global Biologics Manufacturing

The global landscape for biologics manufacturing is undergoing a fundamental shift, driven by a convergence of policy, trade, and security pressures. The stability of the global supply network is now being challenged by factors like the proposed BIOSECURE Act, the possibility of significant tariffs on foreign-made drugs, and the persistent fragility of supply chains exposed during COVID-19.

Drug developers can no longer treat offshore risks as hypothetical; the calculus for manufacturing location has changed, with cost no longer necessarily offsetting the risks to timelines and long-term product value. The seven forces reshaping the industry include geopolitical tension, trade volatility, inconsistent regulatory access, and exposure to intellectual property and data security risks. Forward-looking companies are now conducting early risk assessments and securing U.S. capacity to future-proof their pipelines and avoid costly, rushed transfers.

Explore the seven critical forces reshaping global biologics manufacturing and the practical steps sponsors can take to proactively de-risk their supply chains.